Antibiotic Doesn ’ t Prevent Lung Complication After Stem Cell Transplant
Findings were so dismal that clinical trial was stopped early
Conditions: Idiopathic Pulmonary Fibrosis; Emphysema or COPD Interventions: Biological: CD3/CD19 negative hematopoietic stem cells; Drug: Rituximab; Drug: Alemtuzumab; Drug: Fludarabine; Drug: Thiotepa; Drug: G-CSF; Drug: Hydroxyurea Sponsor: Paul Szabolcs Not yet recruiting
Scientists at the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital have uncovered a novel, two-agent immunotherapy combination that worked surprisingly well in animal models with malignant mesothelioma. The discovery has sparked new optimism for immunotherapy, which has struggled to provide consistently positive results with aggressive cancers such as mesothelioma. “This is the beginning of a new story of hope, a new combination of immunotherapy,” Dr. Mark Poznansky, director of the VIC and associate professor at Harvard Medical School, told Asbestos.com. “It worked quite well in a...
This study demonstrates that small peptide domains derived from native protein amelogenin can be utilized to construct a mineral layer on damaged human enamel in vitro. Six groups were prepared to carry out remineralization on artificially created lesions on enamel: (1) no treatment, (2) Ca2+ and PO43- only, (3) 1100 ppm fluoride (F), (4) 20 000 ppm F, (5) 1100 ppm F and peptide, and (6) peptide alone. While the 1100 ppm F sample (indicative of common F content of toothpaste for homecare) did not deliver F to the thinly deposited mineral layer, high F test sample (indicative of clinical varnish treatment) formed mainly C...
Publication date: Available online 12 February 2018 Source:Respiratory Investigation Author(s): Ayako Shimada, Jiro Terada, Kenji Tsushima, Yoshihisa Tateishi, Ryuzo Abe, Shigeto Oda, Motomu Kobayashi, Masaomi Yamane, Takahiro Oto, Koichiro Tatsumi Cases of extracorporeal membrane oxygenation (ECMO) bridged lung transplantation (LTx) are rare in Japan because an allocation system to prioritize patients based on urgency remains to be established. For critically ill patients who cannot wait for a brain-dead donor LTx, ECMO bridge to living-donor LTx may be the only practical option. A 21-year-old woman with pleuroparenchyma...
Conclusions We here demonstrate for the first time that pulmonary transplantation of human iPSC-derived macrophages leads to pulmonary engraftment, their in situ differentiation to an AM phenotype and a reduction of alveolar proteinosis in a humanized PAP model. To our knowledge, this finding presents the first proof-of-concept for the therapeutic potential of iPSC-derived cells in a pulmonary disease and may have profound implications beyond the rare disease of PAP. PMID: 29652170 [PubMed - as supplied by publisher]
We describe our unique approach of aiming for ASCT one year after HT so that patients can remain in hematological remission with current chemotherapy and to allow patients complete recovery from OHT.
Heart transplantation remains the standard treatment for end stage heart failure patients. However, hemodynamic instability after brain death (BD) could affect posttransplant graft function. Conditioned medium (CM) from bone marrow derived mesenchymal stem cells (MSCs) was found to protect the myocardium against ischemia/reperfusion (IR), this finding appears to be mediated via activation of the phosphatidylinositol 3 kinase (PI3K) signalling. We hypothesized that CM added to a preservation solution (Custodiol) improves in vivo left ventricular (LV) graft function after transplantation.
Ex vivo lung perfusion (EVLP) has emerged as a modern preservation technique developed to evaluate candidate donor lungs in a normothermic and metabolically active state. Donor leukocytes are linked to the development of transplant related ischemia reperfusion injury, primary graft dysfunction, and acute rejection. Pharmacologic strategies to enhance donor leukocyte depletion during EVLP have not yet been described. Plerixafor (Mozobil) is a clinically available CXCR4 receptor antagonist, which disrupts the interaction between CXCR4 and SDF-1 α and facilitates mobilization of hematopoietic stem cells into peripheral circulation.
For clinical application of cardiomyocytes derived from induced pluripotent stem cells (iPSC-CM), immunological response to transplants should be great concern; however, innate immunological response after in vivo transplantation has not been fully elucidated. We hypothesized that natural killer cells (NKCs) may play an important role in innate immune rejection to transplanted iPSC-CMs.
Contraction of interventricular septum (IVS) is an important component of right ventricular (RV) function. We investigated the effects of IVS stem cell injections on RV function in patients with non-ischemic dilated cardiomyopathy (DCM).